Equities research analysts predict that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will report earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.28). Sangamo Therapeutics posted earnings per share of ($0.01) during the same quarter last year, which suggests a negative year-over-year growth rate of 3,300%. The business is scheduled to announce its next earnings report on Wednesday, November 3rd.
According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.11). For the next year, analysts expect that the business will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.94) to ($0.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Sangamo Therapeutics had a negative net margin of 98.21% and a negative return on equity of 27.99%. The firm had revenue of $27.87 million for the quarter, compared to the consensus estimate of $29.72 million.
SGMO stock traded up $0.09 during midday trading on Friday, hitting $8.92. 21,194 shares of the stock traded hands, compared to its average volume of 1,135,135. The stock’s fifty day simple moving average is $9.56 and its 200-day simple moving average is $10.53. Sangamo Therapeutics has a 1-year low of $8.60 and a 1-year high of $19.43. The firm has a market cap of $1.30 billion, a P/E ratio of -9.29 and a beta of 1.66.
Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley increased its holdings in Sangamo Therapeutics by 24.7% during the 2nd quarter. Morgan Stanley now owns 891,147 shares of the biopharmaceutical company’s stock worth $10,667,000 after purchasing an additional 176,775 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Sangamo Therapeutics by 4.7% during the second quarter. Wells Fargo & Company MN now owns 690,197 shares of the biopharmaceutical company’s stock worth $8,261,000 after acquiring an additional 31,242 shares in the last quarter. Fort Sheridan Advisors LLC lifted its position in shares of Sangamo Therapeutics by 2.3% during the second quarter. Fort Sheridan Advisors LLC now owns 77,680 shares of the biopharmaceutical company’s stock worth $930,000 after acquiring an additional 1,735 shares in the last quarter. Invesco Ltd. lifted its position in shares of Sangamo Therapeutics by 5.9% during the second quarter. Invesco Ltd. now owns 801,873 shares of the biopharmaceutical company’s stock worth $9,599,000 after acquiring an additional 44,410 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY raised its position in shares of Sangamo Therapeutics by 108,530.3% in the second quarter. Metropolitan Life Insurance Co NY now owns 35,848 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 35,815 shares in the last quarter. 52.41% of the stock is currently owned by hedge funds and other institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.
See Also: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.